Paul Hastings, Baker Botts Drive $400M Animal Health Deal

Law360 (May 13, 2020, 1:16 PM EDT) -- The animal unit of New Jersey-based Merck & Co., advised by Paul Hastings and Baker Botts, has agreed to buy the rights to Sentinel-branded animal tabs and chews products in the U.S. for roughly $400 million, the companies said Wednesday.

The agreement sees Merck Animal Health picking up the rights to Sentinel-branded products in the U.S. from France-based Virbac, which makes supplements and drugs sold in pet stores and veterinary clinics, according to a statement. Merck Animal Health will make a cash payment of about $400 million at the time the deal closes.

Virbac's Sentinel-branded products protect dogs from internal and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!